menu
    • menu
    [{"orgOrder":0,"company":"Synthekine","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synthekine \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Synthekine \/ Sanofi"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"STK-012","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Deerfield Management","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Deerfield Management"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Series C Financing","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ The Column Group"},{"orgOrder":0,"company":"Synthekine","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series A Financing","leadProduct":"STK-012","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Canaan Partners","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Canaan Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Synthekine

    Menu

    Synthekine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYNCAR-001,STK-009

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Synthekine Granted FDA Fast Track Designation For CD19 CAR-T Therapy in Lupus

                            Details : SYNCAR-001, an autologous CD19-targeted CAR-T in combination with STK-009 is a human orthogonal IL-2 cytokine is being evaluated for the treatment of lupus without lymphodepletion.

                            Product Name : SYNCAR-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            April 09, 2024

                            Lead Product(s) : SYNCAR-001,STK-009

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYNCAR-001,STK-009

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Synthekine Announces FDA Clearance for CD19 CAR-T and IL-2 Combination Therapy for Lupus

                            Details : SYNCAR-001, an autologous CD19-targeted CAR-T in combination with STK-009 is a human orthogonal IL-2 cytokine is being evaluated for the treatment of lupus without lymphodepletion.

                            Product Name : SYNCAR-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 26, 2024

                            Lead Product(s) : SYNCAR-001,STK-009

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Synthekine Partners Sanofi to Develop Selective IL-10 Agonists for Inflammatory Diseases

                            Details : The collaboration aims to support the development of selective IL-10 agonists, which play a key role in immune regulation for the treatment of inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $40.0 million

                            January 29, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STK-012,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in Phase 1b Clinical Trial of Synthekine’s α/β Biased IL-2, STK-012, for Treatment of ...

                            Details : STK-012 is the first-in-class alpha/beta biased IL-2 has potential to decouple efficacy and toxicity of IL-2, which is investigated for the treatment of treatment of solid tumors.

                            Product Name : STK-012

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 28, 2023

                            Lead Product(s) : STK-012,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SYNCAR-001,STK-009

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy...

                            Details : STK-009 + SYNCAR-001 is a two-component therapy consisting of SYNCAR-001, a CD19-targeting chimeric antigen receptor T cell (CAR-T) which expresses an engineered IL-2 receptor allowing it to selectively receive a signal from STK-009, an engineered pegyla...

                            Product Name : SYNCAR-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            July 27, 2023

                            Lead Product(s) : SYNCAR-001,STK-009

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STK-012,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The Column Group

                            Deal Size : $100.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics

                            Details : Proceeds of the financing will be used to advance Synthekine’s differentiated therapeutic pipeline, led by its alpha/beta-biased IL-2 partial agonist, STK-012, which is currently in a Phase 1 clinical trial.

                            Product Name : STK-012

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : STK-012,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The Column Group

                            Deal Size : $100.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STK-012,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platform...

                            Details : In syngeneic tumor models, subcutaneously injected STK-012 mouse surrogate demonstrated reduced toxicities and improved efficacy relative to mouse wild-type IL-2 or a non-α IL-2. In cynomolgus monkeys, acute lung inflammation was induced by aldesleukin ...

                            Product Name : STK-012

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 04, 2022

                            Lead Product(s) : STK-012,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STK-012,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of So...

                            Details : In non-human primate studies, STK-012 avoided lymphopenia, NK cell activation and CLS induction, which was observed with both aldesleukin and a non-alpha-IL-2 agent.

                            Product Name : STK-012

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 02, 2022

                            Lead Product(s) : STK-012,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STK-012,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors

                            Details : Preclinical studies demonstrated a mouse surrogate of STK-012 achieved superior tumor regression compared to both wild-type mouse IL-2 and a non-alpha-IL-2 agent, representing a different approach to biasing IL-2.

                            Product Name : STK-012

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 28, 2021

                            Lead Product(s) : STK-012,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Synthekine

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STK-012

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Deerfield Management

                            Deal Size : $107.5 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Synthekine Announces $107.5 Million Oversubscribed Series B Financing

                            Details : Synthekine’s therapeutic pipeline is led by its selective IL-2 partial agonist, STK-012, and its orthogonal IL-2 and CD-19 CAR-T system, STK-009 and SYNCAR-001.

                            Product Name : STK-012

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 06, 2021

                            Lead Product(s) : STK-012

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Deerfield Management

                            Deal Size : $107.5 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth